Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 187

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Causes and consequences of methamphetamine and MDMA toxicity

Open access
Quinton, Maria S., Yamamoto, Bryan K.·2006·The AAPS Journal
DOI 10.1007/bf02854904
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/bf02854904

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 92

  1. Hotchkiss AJ, Morgan ME, Gibb JW. The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities.Life Sci. 1979;25:1373–1378. · DOI · Paper page
  2. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine.Brain Res. 1980;181:151–160. · DOI · Paper page
  3. Ricaurte GA, Schuster CR, Seiden LS. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study.Brain Res. 1980;193:153–163. · DOI · Paper page
  4. Stephans SE, Yamamoto BK. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux.Synapse. 1994;17:203–209. · DOI · Paper page
  5. Raiteri M, Cerrito F, Cervoni AM, Levi G. Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine.J Pharmacol Exp Ther. 1979;208:195–202. · DOI · Paper page
  6. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture.J Neurosci Res. 1990;26:428–435. · DOI · Paper page
  7. Nash JF, Yamamoto BK. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine.Brain Res. 1992;581:237–243. · DOI · Paper page
  8. Mark KA, Soghomonian JJ, Yamamoto BK. High-dose methamphetamine acutely activates the striatoningral pathway to increase striatal glutamate and mediate long-term dopamine toxicity.J Neurosci. 2004;24:11449–11456. · DOI · Paper page
  9. Yamamoto BK, Gudelsky G, Stephans SE. Amphetamine neurotoxicity. Roles for dopamine, glutamate and oxidative stress. In:Progress in HPLC-HPCE. Utrecht, The Netherlands: VSP; 1998;223–244.
  10. Rocher C, Gardier AM. Effects of repeated systemic administration of d-fenfluramine on serotonin and glutamate release in rat ventral hippocampus: comparison with methamphetamine using in vivo microdialysis.Naunyn Schmiedebergs Arch Pharmacol. 2001;363:422–428. · DOI
  11. Brown JM, Yamamoto BK. Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress.Pharmacol Ther. 2003;99:45–53. · DOI · Paper page
  12. Brown JM, Quinton MS, Yamamoto BK. Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite.J Neurochem. 2005;95:429–436. · DOI
  13. Hotchkiss AJ, Gibb JW. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain.J Pharmacol Exp Ther. 1980;214:257–262. · DOI · Paper page
  14. Schmidt CJ, Taylor VL. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine.Biochem Pharmacol. 1987;36:4095–4102. · DOI · Paper page
  15. Eisch AJ, Marshall JF. Methamphetamine neurotoxicity: dissociation of striatal dopamine terminal damage from parietal cortical cell body injury.Synapse. 1998;30:433–445. · doi:10.1002/(sici)1098-2396(199812)30:4<433::aid-syn10>3.0.co;2-o
  16. Seiden LS, Fischman MW, Schuster CR. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys.Drug Alcohol Depend. 1976;1:215–219. · DOI · Paper page
  17. Finnegan KT, Ricaurte G, Seiden LS, Schuster CR. Altered sensitivity to d-methylamphetamine, apomorphine, and haloperidol in rhesus monkeys depleted of caudate dopamine by repeated administration of d-methylamphetamine.Psychopharmacology (Berl). 1982;77:43–52. · DOI
  18. Green AR, De Souza RJ, Williams JL, Murray TK, Cross AJ. The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: evidence for the protective effect of chlormethiazole.Neuropharmacology. 1992;31:315–321. · DOI
  19. Woolverton WL, Ricaurte GA, Forno LS, Seiden LS. Long-term effects of chronic methamphetamine administration in rhesus monkeys.Brain Res. 1989;486:73–78. · DOI · Paper page
  20. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, de Souza EB. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.J Pharmacol Exp Ther. 1987;242:911–916. · DOI · Paper page
  21. O'Hearn E, Battaglia G, de Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity.J Neurosci. 1988;8:2788–2803. · DOI · Paper page
  22. Finnegan KT, Ricaurte GA, Ritchie LD, Irwin I, Peroutka SJ, Langston JW. Orally administered MDMA causes a long-term depletion of serotonin in rat brain.Brain Res. 1988;447:141–144. · DOI
  23. Ricaurte GA, Forno LS, Wilson MA. (+/−)3,4-Methylene-dioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates.JAMA. 1988;260:51–55. · DOI
  24. Steele TD, McCann UD, Ricaurte GA. 3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): pharmacology and toxicology in animals and humans.Addiction. 1994;89:539–551. · DOI · Paper page
  25. McCann UD, Ridenour A, Shaham Y, Ricaurte GA. Serotonin neurotoxicity after (+/−)3,4-methylenedioxymethamphetamine (MDMA; “Ecstasy”): a controlled study in humans.Neuropsychopharmacology. 1994;10:129–138. · DOI · Paper page
  26. Malberg JE, Sabol KE, Seiden LS. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat.J Pharmacol Exp Ther. 1996;278:258–267. · DOI
  27. Fleckenstein AE, Wilkins DG, Gibb JW, Hanson GR. Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration.J Pharmacol Exp Ther. 1997;283:281–285. · DOI
  28. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain.Brain Res. 1982;235:93–103. · DOI · Paper page
  29. Eisch AJ, Schmued LC, Marshall JF. Characterizing cortical neuron injury with fluoro-jade labeling after a neurotoxic regimen of methamphetamine.Synapse. 1998;30:329–333. · DOI
  30. O'Dell SJ, Marshall JF. Neurotoxic regimens of methamphetamine induce persistent expression of phospho-c-Jun in somatosensory cortex and substantia nigra.Synapse. 2005;55:137–147. · DOI
  31. O'Callaghan JP, Sriram K. Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity.Expert Opin Drug Saf. 2005;4:433–442. · DOI · Paper page
  32. Pu C, Fisher JE, Cappon GD, Vorhees CV. The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum.Brain Res. 1994;649:217–224. · DOI
  33. Miller DB, O'Callaghan JP. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse.J Pharmacol Exp Ther. 1994;270:752–760. · DOI · Paper page
  34. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain.J Pharmacol Exp Ther. 1987;241:338–345. · DOI · Paper page
  35. Stone DM, Johnson M, Hanson GR, Gibb JW. Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites.Eur J Pharmacol. 1989;172:93–97. · DOI
  36. Gibb JW, Johnson M, Hanson GR. Neurochemical basis of neurotoxicity.Neurotoxicology. 1990;11:317–321.
  37. Wagner GC, Carelli RM, Jarvis MF. Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion.Neuropharmacology. 1986;25:559–561. · DOI
  38. Gudelsky GA. Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin.J Neural Transm. 1996;103:1397–1404. · DOI
  39. Colado MI, Green AR. The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents “ecstasy”-induced neurodegeneration of 5-hydroxytryptamine neurones.Eur J Pharmacol. 1995;280:343–346. · DOI
  40. Fukami G, Hashimoto K, Koike K, Okamura N, Shimizu E, Iyo M. Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine.Brain Res. 2004;1016:90–95 · DOI
  41. Stone DM, Johnson M, Hanson GR, Gibb JW. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine.J Pharmacol Exp Ther. 1988;247:79–87. · DOI · Paper page
  42. Schmidt CJ, Ritter JK, Sonsalla PK, Hanson GR, Gibb JW. Role of dopamine in the neurotoxic effects of methamphetamine.J Pharmacol Exp Ther. 1985;233:539–544. · DOI · Paper page
  43. Gudelsky GA, Nash JF. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions.J Neurochem. 1996;66:243–249. · DOI · Paper page
  44. Marek GJ, Vosmer G, Seiden LS. Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons.Brain Res. 1990;513:274–279. · DOI
  45. Sprague JE, Everman SL, Nichols DE. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine.Neurotoxicology. 1998;19:427–441.
  46. Breier JM, Bankson MG, Yamamoto BK. L-tyrosine contributes to (+)-3,4-methylenedioxymethamphetamine-induced serotonin depletions.J Neurosci. 2006;26:290–299. · DOI
  47. Bai F, Jones DC, Lau SS, Monks TJ. Serotonergic neurotoxicity of 3,4-(+/−)-methylenedioxyamphetamine and 3,4-(+/−)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase.Chem Res Toxicol. 2001;14:863–870. · DOI
  48. Jones DC, Lau SS, Monks TJ. Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells.J Pharmacol Exp Ther. 2004;311:298–306. · DOI
  49. Jiang XR, Wrona MZ, Alguindigue SS, Dryhurst G. Reactions of the putative neurotoxin tryptamine-4,5-dione with L-cysteine and other thiols.Chem Res Toxicol. 2004;17:357–369. · DOI
  50. Colado MI, O'Shea E, Granados R, Murray TK, Green AR. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA (‘ecstasy’) and p-chloroamphetamine but not the degeneration following fenfluramine.Br J Pharmacol. 1997;121:889–900. · DOI · Paper page
  51. Shankaran M, Yamamoto BK, Gudelsky GA. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine.Eur J Pharmacol. 1999;385:103–110. · DOI
  52. Shankaran M, Yamamoto BK, Gudelsky GA. Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum.J Neurochem. 1999;72:2516–2522. · DOI
  53. Giovanni A, Liang LP, Hastings TG, Zigmond MJ. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine.J Neurochem. 1995;64:1819–1825. · DOI · Paper page
  54. Iman SZ, Yazal J, Newport GD, et al. Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts.Ann NY Acad Sci. 2001;939:366–380. · DOI · Paper page
  55. Shankaran M, Yamamoto BK, Gudelsky GA. Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT.Synapse. 2001;40:55–64. · doi:10.1002/1098-2396(200104)40:1<55::aid-syn1026>3.0.co;2-o
  56. Sprague JE, Nichols DE. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits.J Pharmacol Exp Ther. 1995;273:667–673. · DOI
  57. Yamamoto BK, Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress.J Pharmacol Exp Ther. 1998;287:107–114. · DOI · Paper page
  58. Acikgoz O, Gonenc S, Kayatekin BM, et al. Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum.Brain Res. 1998;813:200–202. · DOI
  59. Gluck MR, Moy LY, Jayatilleke E, Hogan KA, Manzino L, Sonsalla PK. Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment.J Neurochem. 2001;79:152–160. · DOI
  60. Itzhak Y, Ali SF. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo.J Neurochem. 1996;67:1770–1773. · DOI · Paper page
  61. Colado MI, Camarero J, Mechan AO, et al. A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on dopamine neurones in mouse brain.Br J Pharmacol. 2001;134:1711–1723. · DOI
  62. Darvesh AS, Yamamoto BK, Gudelsky GA. Evidence for the involvement of nitric oxide in 3,4-methylenedioxymethamphetamine-induced serotonin depletion in the rat brain.J Pharmacol Exp Ther. 2005;312:694–701. · DOI
  63. Kuhn DM, Sadidi M, Liu X. Peroxynitrite-induced nitration of tyrosine hydroxylase: identification of tyrosines 423, 428, and 432 as sites of modification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry and tyrosine-scanning mutagenesis.J Biol Chem. 2002;277:14336–14342. · DOI
  64. Sattler R, Tymianski M. Molecular mechanisms of calcium-dependent excitotoxicity.J Mol Med. 2000; 78:3–13. · DOI · Paper page
  65. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders.N Engl J Med. 1994;330:613–622. · DOI · Paper page
  66. Sonsalla PK, Nicklas WJ, Heikkila RE. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity.Science. 1989;243:398–400. · DOI · Paper page
  67. Finnegan KT, Taraska T. Effects of glutamate antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine-induced striatal dopamine release in vivo.J Neurochem. 1996;66:1949–1958. · DOI
  68. Albers DS, Sonsalla PK. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents.J Pharmacol Exp Ther. 1995;275:1104–1114. · DOI · Paper page
  69. Battaglia G, Fornai F, Busceti CL, et al. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity.J Neurosci. 2002;22:2135–2141. · DOI
  70. Burrows KB, Meshul CK. Methamphetamine alters presynaptic glutamate immunoreactivity in the caudate nucleus and motor cortex.Synapse. 1997;27:133–144. · DOI
  71. Siman R, Noszek JC, Kegerise C. Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage.J Neurosci. 1989;9:1579–1590. · DOI · Paper page
  72. Minger SL, Geddes JW, Holtz ML, et al. Glutamate receptor antagonists inhibit calpain-mediated cytoskeletal proteolysis in focal cerebral ischemia.Brain Res. 1998;810:181–199. · DOI
  73. Staszewski RD. Yamamoto BK. Methamphetamine-induced spectrin proteolysis in the rat striatum.J Neurochem. 2006;96:1267–1276. · DOI
  74. Schmidt HH, Hofmann H, Schindler U, Shutenko ZS, Cunningham DD, Feelisch M. No NO from NO synthase.Proc Natl Acad Sci USA. 1996;93:14492–14497. · DOI · Paper page
  75. Kahlert S, Zundorf G, Reiser G. Glutamate-mediated influx of extracellular Ca2+ is coupled with reactive oxygen species generation in cultured hippocampal neurons but not in astrocytes.J Neurosci Res. 2005;79:262–271. · DOI
  76. Chan P, Di Monte DA, Luo JJ, DeLanney LE, Irwin I, Langston JW. Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity.J Neurochem. 1994;62:2484–2487. · DOI
  77. Nixdorf WL, Burrows KB, Gudelsky GA, Yamamoto BK. Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate.J Neurochem. 2001;77:647–654. · DOI
  78. Albers DS, Zeevalk GD, Sonsalla PK. Damage to dopaminergic nerve terminals in mice by combined treatment of intrastriatal malonate with systemic methamphetamine or MPTP.Brain Res. 1996;718:217–220. · DOI
  79. Burrows KB, Nixdorf WL, Yamamoto BK. Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines.J Pharmacol Exp Ther. 2000;292:853–860. · DOI
  80. Stephans SE, Whittingham TS, Douglas AJ, Lust WD, Yamamoto BK. Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum.J Neurochem. 1998;71:613–621. · DOI
  81. Wan FJ, Lin HC, Kang BH, Tseng CJ, Tung CS. D-amphetamine-induced depletion of energy and dopamine in the rat striatum is attenuated by nicotinamide pretreatment.Brain Res Bull. 1999;50:167–171. · DOI
  82. Zeevalk GD, Derr-Yellin E, Nicklas WJ. Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade.J Pharmacol Exp Ther. 1995;275:1124–1130. · DOI
  83. Darvesh AS, Shankaran M, Gudelsky GA. 3,4-Methylenedioxymethamphetamine produces glycogenolysis and increases the extracellular concentration of glucose in the rat brain.J Pharmacol Exp Ther. 2002;301:138–144. · DOI
  84. Burrows KB, Gudelsky G, Yamamoto BK. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration.Eur J Pharmacol. 2000;398:11–18. · DOI
  85. Kushnareva YE, Wiley SE, Ward MW, Andreyev AY, Murphy AN. Excitotoxic injury to mitochondria isolated from cultured neurons.J Biol Chem. 2005;280:28894–28902. · DOI
  86. Brown JM, Hanson GR, Fleckenstein AE, Methamphetamine rapidly decreases vesicular dopamine uptake.J Neurochem. 2000;74:2221–2223. · DOI · Paper page
  87. Riddle EL, Topham MK, Haycock JW, Hanson GR, Fleckenstein AE. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine.Eur J Pharmacol. 2002; 449:71–74. · DOI
  88. Eyerman DJ, Yamamoto BK. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum.J Pharmacol Exp Ther. 2005;312:160–169. · DOI
  89. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons involves antophagy and upregulation of dopamine synthesis.J Neurosci. 2002;22:8951–8960. · DOI · Paper page
  90. Hatzipetros T, Yamamoto BK. Dopaminergic and GABAergic modulation of glutamate release from subthalamic nucleus efferents to the rat substantia nigra.Brain Res. 2006;1076:60–67. · doi:10.1016/j.brainres.2006.01.015
  91. Bustamante D, You ZB, Castel MN, et al. Effect of single and repeated methamphetamine treatment on neurotransmitter release in substantia nigra and neostriatum of the rat.J Neurochem. 2002:83:645–654. · DOI
  92. Stanimirovic DB, Wong J, Ball R, Durkin JP. Free radical-induced endothelial membrane dysfunction at the site of blood-brain barrier: relationship between lipid peroxidation, Na,K-ATPase activity, and 51 Cr release.Neurochem Res. 1995;20:1417–1427. · DOI

Cited by

See all 187

Metadata

Authors
Quinton, M. S., & Yamamoto, B. K.
Venue
The AAPS Journal
Publisher
Springer Science and Business Media LLC
Published
2006-06
Volume
8
Issue
2
Pages
E337-E337
ISSN
1550-7416 (ISSN-L)
DOI
10.1007/bf02854904
OpenAlex
W1992085755
Cited by
187
References
3
FWCI
5.67
Type
journal article
Language
en
Open access
bronze
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.